SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?


To: betty moyers who wrote (11439)7/14/1998 11:15:00 AM
From: Mkilloran  Respond to of 23519
 
Betty...I agree that Vivus should benefit from the sales base that they have built already in the USA.
.
They could negotiate a deal that rewards them for the base ....using a formula ie adv number of scripts per week during qtr 4...with the deal signed in the 3rd qtr to take over Jan 1st 1999.

Visus gets ~$7.00 per script for new scripts over the base determined in the 4th qtr...they would get ~$7.00 + xxx for the base number going foward.

Like the CEO said...everythings up for negotiations.